GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer

This study has been terminated.

( Based on futility analysis showing <30% chance of meeting primary endpoint. )

Study NCT00089856 Information provided by Cell Genesys

First Received: August 16, 2004 Last Updated: November 3, 2008 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study has been terminated.
Study Completion Date:	October 2008
Primary Completion Date:	October 2008 (Final data collection date for primary outcome measure)